Smart manufacturing is “nearly universal” with 95% of manufacturers saying they are using or evaluating smart technology, according to a new survey from Rockwell Automation.
The CDMO completed site construction and infrastructure installation at its 50,000-square-foot facility, with full-scale GMP production slated for this summer.
While the process has been a buzzword for years, offering an alternative to traditional batch manufacturing, industry uptake has been slow. However, the tide may be turning.
U.S. Pharmacopeia CEO Ronald Piervincenzi told lawmakers that advanced manufacturing technologies will better enable production of pharmaceuticals and pharma ingredients.
The Tar Heel State’s decades-long focus on economic development in life sciences and pharma manufacturing is bearing fruit, as it looks to rival the Bay Area and Boston.
Part of Danaher Corporation, Cytiva’s strategic investment in Asia-Pacific, Europe, and the United States aligns with its long-term growth plan to better serve customers.
While Big Pharma companies have announced $270 billion in domestic investments, lab leasing declined significantly in Q1 2025, finds JLL’s U.S. Life Sciences Property Report.
Equipped with high-speed lines, robotics, and automated systems, the site started commercial production at the end of 2024 after completing construction in only two years.
The CDMO is building identical large-scale production facilities in the U.S. and Denmark, designed to modularly and seamlessly integrate manufacturing regardless of location.
The company is expanding the site’s sterile fill-finish capabilities while sunsetting traditional batch, solid dose production and adopting continuous manufacturing.
Despite the potential threat of tariffs, trade policy did not factor into the India-based CRDMO’s purchase of a Baltimore biologics site from Emergent BioSolutions.
More than 300 comments have been posted in response to a Department of Commerce investigation into the importation of certain pharmaceuticals and pharma ingredients.
CEO Padraig McDonnell contends that Biovectra’s capabilities are in the “sweet spot” of GLP-1s and complex chemistries, with strong medium- and long-term growth potential.
The Minnesota-based company is now being covered by William Blair analyst Max Smock who spoke with Pharma Manufacturing about Lifecore’s position in the CDMO landscape.
With a record number of FDA biosimilar approvals in 2024, CMOs specializing in biologics can expect to see higher biosimilar volumes, according to GlobalData.
PhRMA warned that President Trump’s executive order on most favored nation would jeopardize hundreds of billions of dollars in planned U.S. investments by its members.
The company warned that if the executive order goes into effect, Roche’s ability to invest $50 billion in its U.S. R&D and manufacturing sites will be in question.
CEO Bill Anderson said that the company has “considerable” production capabilities in both the U.S. and Europe but has no immediate plans to shift them.
CEO Christophe Weber said that the investment is not a new strategy and reflects the position of the U.S. as the world’s leading market for biopharma innovation.
The announcement comes after President Trump signed an executive order aimed at expediting the approval process for domestic pharmaceutical manufacturing facilities.
Expansions at sites in Le Mans and Mourenx, France have solidified the CDMO’s position in targeting the hot antibody-drug conjugate and peptide purification markets.
Dave Ricks said Lilly supports the administration’s goal of bringing pharma manufacturing back to the U.S. but doesn’t see tariffs as the “right mechanism” for reshoring.
CEO Albert Bourla said that President Trump’s threat of pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and R&D.
CEO Rob Michael told analysts that the company is investing more than $10 billion in the U.S. to support volume growth and expansion into new areas such as obesity.
